|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Protzel C, Maruschke M and Hakenberg OW:
Epidemiology, aetiology, and pathogenesis of renal cell carcinoma.
Eur Urol Supp. 11:52–59. 2012. View Article : Google Scholar
|
|
3
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: SEER cancer statistics review, 1975–2010. National Cancer
Institute (Bethesda, MD). 2013.http://seer.cancer.gov/csr/1975_2010/December
19–20132013.
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Djuranovic S, Nahvi A and Green R: A
parsimonious model for gene regulation by miRNAs. Science.
331:550–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao Y, Zhao H, Lu Y, Li H and Yan G:
MicroRNAs as potential diagnostic biomarkers in renal cell
carcinoma. Tumour Biol. 35:11041–11050. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Al-Ali BM, Ress AL, Gerger A and Pichler
M: MicroRNAs in renal cell carcinoma: Implications for
pathogenesis, diagnosis, prognosis and therapy. Anticancer Res.
32:3727–3732. 2012.PubMed/NCBI
|
|
8
|
Lawrie CH, Gal S, Dunlop HM, Pushkaran B,
Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J,
Wainscoat JS, et al: Detection of elevated levels of
tumour-associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weber JA, Baxter DH, Zhang S, Huang DY,
Huang KH, Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12
body fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu
X, Xiao P, Shi H, Wang R, Chen L, et al: miR-141 Is a key regulator
of renal cell carcinoma proliferation and metastasis by controlling
EphA2 expression. Clin Cancer Res. 20:2617–2630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakada C, Matsuura K, Tsukamoto Y,
Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida
T, Sato F, et al: Genome-wide microRNA expression profiling in
renal cell carcinoma: Significant down-regulation of miR-141 and
miR-200c. J Pathol. 216:418–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jung M, Mollenkopf HJ, Grimm C, Wagner I,
Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach
H, et al: MicroRNA profiling of clear cell renal cell cancer
identifies a robust signature to define renal malignancy. J Cell
Mol Med. 13:3918–3928. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yi Z, Fu Y, Zhao S, Zhang X and Ma C:
Differential expression of miRNA patterns in renal cell carcinoma
and nontumorous tissues. J Cancer Res Clin Oncol. 136:855–862.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Juan D, Alexe G, Antes T, Liu H,
Madabhushi A, Delisi C, Ganesan S, Bhanot G and Liou LS:
Identification of a microRNA panel for clear-cell kidney cancer.
Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weng L, Wu X, Gao H, Mu B, Li X, Wang JH,
Guo C, Jin JM, Chen Z, Covarrubias M, et al: MicroRNA profiling of
clear cell renal cell carcinoma by whole-genome small RNA deep
sequencing of paired frozen and formalin-fixed, paraffin-embedded
tissue specimens. J Pathol. 222:41–51. 2010.PubMed/NCBI
|
|
18
|
Duns G, van den Berg A, van Dijk MC, van
Duivenbode I, Giezen C, Kluiver J, van Goor H, Hofstra RM, van den
Berg E and Kok K: The entire miR-200 seed family is strongly
deregulated in clear cell renal cell cancer compared to the
proximal tubular epithelial cells of the kidney. Genes Chromosomes
Cancer. 52:165–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
Aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Chen X, Han W, Ruan A, Chen L,
Wang R, Xu Z, Xiao P, Lu X, Zhao Y, et al: miR-200c targets CDK2
and suppresses tumorigenesis in renal cell carcinoma. Mol Cancer
Res. 13:1567–1577. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lopez-Beltran A, Scarpelli M, Montironi R
and Kirkali Z: 2004 WHO classification of the renal tumors of the
adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Turchinovich A, Weiz L and Burwinkel B:
Extracellular miRNAs: The mystery of their origin and function.
Trends Biochem Sci. 37:460–465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heneghan HM, Miller N and Kerin MJ:
Circulating miRNA signatures: Promising prognostic tools for
cancer. J Clin Oncol. 28:e573–e576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scheffer AR, Holdenrieder S, Kristiansen
G, von Ruecker A, Muller SC and Ellinger J: Circulating microRNAs
in serum: Novel biomarkers for patients with bladder cancer? World
J Urol. 32:353–358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Westermann AM, Schmidt D, Holdenrieder S,
Moritz R, Semjonow A, Schmidt M, Kristiansen G, Müller SC and
Ellinger J: Serum microRNAs as biomarkers in patients undergoing
prostate biopsy: Results from a prospective multi-center study.
Anticancer Res. 34:665–669. 2014.PubMed/NCBI
|
|
29
|
Sethi S, Ali S, Philip PA and Sarkar FH:
Clinical advances in molecular biomarkers for cancer diagnosis and
therapy. Int J Mol Sci. 14:14771–14784. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bovell LC, Putcha BD, Samuel T and Manne
U: Clinical implications of microRNAs in cancer. Biotech Histochem.
88:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ellinger J, Gevensleben H, Muller SC and
Dietrich D: The emerging role of non-coding circulating RNA as a
biomarker in renal cell carcinoma. Expert Rev Mol Diagn.
16:1059–1065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wotschofsky Z, Busch J, Jung M,
Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller
K, Kristiansen G, et al: Diagnostic and prognostic potential of
differentially expressed miRNAs between metastatic and
non-metastatic renal cell carcinoma at the time of nephrectomy.
Clin Chim Acta. 416:5–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fridman E, Dotan Z, Barshack I, David MB,
Dov A, Tabak S, Zion O, Benjamin S, Benjamin H, Kuker H, et al:
Accurate molecular classification of renal tumors using MicroRNA
expression. J Mol Diagn. 12:687–696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Youssef YM, White NM, Grigull J, Krizova
A, Samy C, Mejia-Guerrero S, Evans A and Yousef GM: Accurate
molecular classification of kidney cancer subtypes using MicroRNA
signature. Eur Urol. 59:721–730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Larne O, Martens-Uzunova E, Hagman Z,
Edsjö A, Lippolis G, den Berg MS, Bjartell A, Jenster G and Ceder
Y: miQ-a novel microRNA based diagnostic and prognostic tool for
prostate cancer. Int J Cancer. 132:2867–2875. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fritz HK, Lindgren D, Ljungberg B, Axelson
H and Dahlback B: The miR(21/10b) ratio as a prognostic marker in
clear cell renal cell carcinoma. Eur J Cancer. 50:1758–1765. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wulfken LM, Moritz R, Ohlmann C,
Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel
G, von Ruecker A, Müller SC and Ellinger J: MicroRNAs in renal cell
carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS
One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Redova M, Poprach A, Nekvindova J, Iliev
R, Radova L, Lakomy R, Svoboda M, Vyzula R and Slaby O: Circulating
miR-378 and miR-451 in serum are potential biomarkers for renal
cell carcinoma. J Transl Med. 10:552012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hauser S, Wulfken LM, Holdenrieder S,
Moritz R, Ohlmann CH, Jung V, Becker F, Herrmann E,
Walgenbach-Brünagel G, von Ruecker A, et al: Analysis of serum
microRNAs (miR-26a-2*miR-191, miR-337-3p and miR-378) as potential
biomarkers in renal cell carcinoma. Cancer Epidemiol. 36:391–394.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang C, Hu J, Lu M, Gu H, Zhou X, Chen X,
Zen K, Zhang CY, Zhang T, Ge J, et al: A panel of five serum miRNAs
as a potential diagnostic tool for early-stage renal cell
carcinoma. Sci Rep. 5:76102015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lou N, Ruan AM, Qiu B, Bao L, Xu YC, Zhao
Y, Sun RL, Zhang ST, Xu GH, Ruan HL, et al: miR-144-3p as a novel
plasma diagnostic biomarker for clear cell renal cell carcinoma.
Urol Oncol. 35:36.e7–36.e14. 2017. View Article : Google Scholar
|
|
42
|
Zhao A, Li G, Peoc'h M, Genin C and
Gigante M: Serum miR-210 as a novel biomarker for molecular
diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol.
94:115–120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iwamoto H, Kanda Y, Sejima T, Osaki M,
Okada F and Takenaka A: Serum miR-210 as a potential biomarker of
early clear cell renal cell carcinoma. Int J Oncol. 44:53–58. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fedorko M, Stanik M, Iliev R,
Redova-Lojova M, Machackova T, Svoboda M, Pacik D, Dolezel J and
Slaby O: Combination of MiR-378 and MiR-210 serum levels enables
sensitive detection of renal cell carcinoma. Int J Mol Sci.
16:23382–23389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li G, Zhao A, Peoch M, Cottier M and
Mottet N: Detection of urinary cell-free miR-210 as a potential
tool of liquid biopsy for clear cell renal cell carcinoma. Urol
Oncol. 35:294–299. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Brase JC, Wuttig D, Kuner R and Sultmann
H: Serum microRNAs as non-invasive biomarkers for cancer. Mol
Cancer. 9:3062010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huang E, Liu R and Chu Y: miRNA-15a/16: As
tumor suppressors and more. Future Oncol. 11:2351–2363. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Roberts TC, Coenen-Stass AM and Wood MJ:
Assessment of RT-qPCR normalization strategies for accurate
quantification of extracellular microRNAs in murine serum. PLoS
One. 9:e892372014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sanders I, Holdenrieder S,
Walgenbach-Brunagel G, von Ruecker A, Kristiansen G, Müller SC and
Ellinger J: Evaluation of reference genes for the analysis of serum
miRNA in patients with prostate cancer, bladder cancer and renal
cell carcinoma. Int J Urol. 19:1017–1025. 2012. View Article : Google Scholar : PubMed/NCBI
|
